Protocol Ledger

NCT07188805 · Phase III · RECRUITING

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ve

Interventional Phase III clinical trial protocol NCT07188805 sponsored by Bayer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-19 Enrollment: 111 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07188805
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07188805
Protocol FieldVerified Registry Value
NCT IdentifierNCT07188805
Consolidated Lead SponsorBayer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment111 participants (ESTIMATED)
Registered Start Date2025-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI